
usd feb pm et
summari compani primarili provid medic technolog product nich busi
price-to-earnings oper ep
base busi princip serv
stabl global health care sector histori
gener solid revenu profit growth howev
compani financi leverag remain higher
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
expect total revenu grow
billion follow growth
support neotract
vascular solut acquisit
confid abil deliv
organ growth
increas invest neotract
urolift acquir product neotract
key driver sale growth especi
recent posit data devic urolift
shonin approv japan
follow bp
expans think
continu expand margin
respect
aid improv oper leverag cost
reduct driven restructur effort
benefit restructur effort
initi like off-set partial
new restructur effort
acceler key invest support
urolift sale commerci infrastructur
recent restructur initi
benefit margin
think risk reward price
forward price-to-earnings
revenu spend weak
rel peer compani rather prefer
make acquisit nich area boost
product portfolio product mix
shift ever sinc two larg acquisit
vascular solut neotract
think took sizabl risk acquir
neotract single-product compani
urolift although growth urolift high
year commerci launch
think acquisit could becom
signific driver futur revenu growth
product compani less
commodit tradit product
portfolio also think execut
integr restructur effort
import
risk recommend target
neotract asian market failur
expand margin price pressur
target base
above-p ep
estim
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
chairman board
senior vice presid
teleflex incorpor engag develop manufactur suppli single-us medic
devic use hospit health care provid common diagnost therapeut procedur
critic care surgic applic sell product hospit healthcar provid
countri combin direct sale forc distributor product
use numer market varieti procedur depend upon one end
market procedur past sever year evolv pure-play medic technolog
compani extens acquisit divestitur program significantli chang
composit portfolio busi expand presenc medic technolog industri
divest busi serv aerospac commerci market categor
oper eight report segment vascular north america intervent north america
anesthesia north america surgic north america emea asia oem
vascular north america segment revenu creat vascular access product
facilit varieti critic care therapi includ administr intraven medic
therapi measur blood pressur take blood sampl singl
punctur site product includ arrow multi- double- single-lumen cathet arrow pressur
inject central venou cathet arrow picc peripher insert central cathet arrow
vascular posit use properli insert cvc picc cathet arrow ez-io system
provid immedi vascular access deliveri medic fluid via intraoss
bone rout
intervent north america segment compris north american compon
vascular solut busi acquir februari well intervent access
cardiac care busi portfolio consist product use intervent cardiologist
intervent radiologist vascular surgeon vein practic portfolio consist clinic
advanc devic treat coronari peripher vascular diseas includ guidelin guid
extens cathet micro-introduc use gain percutan access vasculatur
perform arteri venou catheter procedur turnpik cathet
anesthesia north america segment provid product clinician work primarili
emerg room surgeri critic care set product portfolio includ varieti airway
manag pain manag respiratori care product design help elimin
complic improv procedur effici product primarili market rusch
brand includ endotrach tube tracheostomi tube oral nasal airway laryngoscop face
mask anesthesia circuit expand anesthesia franchis acquisit lma
 global market leader laryng mask respiratori care product princip
consist devic use aerosol medic deliveri oxygen therapi ventil manag
surgic north america segment predominantli compris single-us product product
includ ligat closur product includ applier clip sutur use varieti surgic
procedur access port use minim invas surgic procedur includ robot surgeri
fluid manag product use chest drainag product also includ reusabl hand-held
instrument gener specialti surgic procedur product market deknatel
pill kmedic weck brand name
europ middl east africa emea asia segment design manufactur
distribut medic devic primarili use critic care surgic applic cardiac care
gener serv two end market hospit health care provid home health product
segment wide use acut care set rang diagnost therapeut
procedur gener specialti surgic applic includ urolog
oem segment product servic includ custom extrus perform fiber
devic sold origin equip manufactur oem segment design deliv product
applic wide varieti organ system human bodi product develop
packag
segment includ product materi oper includ
specialti product intervent access product focu oncolog critic care
hospit also provid urolog respiratori anesthesia well capit equip
provid specialti market custom includ home care pre-hospit typic address
emerg altern channel care well hospit
medic devic industri highli competit compet mani compani rang
small start-up enterpris compani larger establish furthermor
market character new product develop technolog chang requir compani
continu develop acquir new product technolog remain competit compet
primarili basi clinic superior innov featur enhanc patient benefit product
reliabl perform custom sale support cost effect major end market
medic product sector hospitals/health care provid revenu medic devic
manufactur home health competitor medic segment includ bard
becton dickinson compani
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc januari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
industri
possibl threat state health
care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
take control hous
repres think see
significantli lower level effort
republican trump administr
tri repeal
hospit spend larg driver medic
equip sale robust
strong economi
tax cut job act tcja individu
mandat roll think
hospit could see pressur lead
sale pressur medic equip
requir american health
insur without requir
expect lower number american
gener see posit long-term
fundament includ increas global
demand qualiti health care age
popul rise outlay lead
steadi flow innov product
 health equip
sub-index rose vs declin
fundament outlook health care
equip sub-industri next month
neutral slightli posit continu
expect compani sub-industri
grow posit macro environ
compani gener benefit
laxer food drug administr fda
technolog advanc sub-industri
also mani product area
equip use non-elect procedur
howev valuat high industri
investor sentiment medic devic
compani appear shaken
volatil late think
higher valuat sub-industri
mostli warrant recent expand
margin robust revenu growth weaker
constant currenc basi expect
revenu sub-industri continu
rise high-single-digit low-double-digit
percentag driven continu pipelin
innov new product emerg market
expans speed new product
come market increas recent
year success effort
fda reduc approv time medic
devic time see price
pressur incess headwind medic
impact trade war appear mild
far medic equip compani
accord medic devic trade
tariff billion medic
technolog export septemb
although chines
govern seek lower health care cost
equip manufactur insul
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
growth outlook expect margin expans driven product mix
higher price set ep estim report oper
ep vs consensu sale increas
growth intervent north america driven vascular solut
acquisit see sale growth contribut
partial off-set slight declin surgic north america segment /keith
et cfra maintain hold opinion share inc
rais target
ep estim compar five-year histor averag price-to-earnings
premium peer reflect acceler sale growth outlook
expect margin expans restructur effort begin produc
result rais ep estim
report oper ep vs
consensu sale increas led growth vascular
north america see sale growth aid neotract
announc enter definit agreement
acquir neotract inc transact valu up-front cash
payment upon achiev certain sale mileston
neotract develop urolift system novel minim invas
technolog treat lower urinari tract symptom due benign prostat
hyperplasia subject customari close condit regulatori approv
deal expect close next day view deal
posit give exposur address market /k snyder
analyst research note compani news
pm et cfra reiter hold opinion share teleflex incorpor
maintain target above-p
ep estim warrant premium due
recent acquir higher growth busi ep vs
equal estim lower ep initi
ep sale increas constant currenc
cc million driven cc growth
intervent north america segment million growth
oem segment million intervent urolog sale includ
tfx urolift devic million total sale
continu see urolift key driver sale growth especi
recent posit data devic urolift shonin approv japan
also obtain pre-market approv pma fda manta devic
global market manta approxim million
expect slow limit launch /kevin huang cfa
incorpor lift target
above-p ep estim warrant
premium peer due recent acquir higher growth busi ep
vs higher estim lift ep
sale increas organ million
acquir neotract busi begin contribut organ
growth debut contribut revenu growth octob
neotract urolift system receiv approv market distribut
japan market approxim million men age
moder sever benign prostat hyperplasia bph symptom seen
physician symptom confid abil deliv
organ growth increas invest
neotract vascular solut support strong momentum /kevin huang cfa
incorpor maintain target
above-p ep estim warrant
slight premium peer due recent acquir higher growth busi
ep vs higher estim lower
ep lift ep
sale increas organ million organ revenu growth
fell short expect time order receiv
distributor product constraint associ supplier manag
maintain organ growth guidanc compar
organ revenu growth start
acquir neotract busi expect contribut organ growth
headwind expect becom slight tailwind neotract promis
growth area gener million revenu repres
incorpor maintain target
above-p next-twelve-month ep estim reflect
strong sale outlook robust margin expans ep vs
higher estim rais ep
sale increas constant currenc million
includ contribut acquisit neotract vascular
solut organ basi revenu grew expect organ
growth acceler remain quarter
year compani remain driven reduc leverag
debt-ebitda march end
howev dont expect effort prevent make
incorpor keep target
ep estim premium peer reflect strong sale
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
